Pharmaceuticals

Luoxin Pharmaceutical

Luoxin Pharmaceutical FY2025 Annual Earnings Release on May 15, 2026 (BJT)

Luoxin Pharmaceutical released FY2026 Q1 earnings on April 22, 2026 (BJT) with actual revenue of CNY 582.73 M and EPS of CNY 0.0226

Luoxin Pharmaceutical released FY2025 earnings on April 22, 2026 (BJT) with actual revenue of CNY 2.273 B and EPS of CNY -0.2718

Luoxin Pharmaceutical released FY2025 Q4 earnings on April 22 (BJT), actual revenue CNY 550.04 M, actual EPS CNY -0.2931

Luoxin Pharmaceutical released FY2025 9 Months Earnings on October 27 (BJT), with actual revenue of CNY 1.723 B and EPS of CNY 0.0035

Luoxin Pharmaceutical released FY2025 Q3 earnings on October 27 (BJT), actual revenue CNY 646.17 M, actual EPS CNY 0.0035

Luoxin Pharmaceutical released FY2025 Q2 earnings on August 27 (BJT), actual revenue CNY 594.52 M, actual EPS CNY 0.01

Luoxin Pharmaceutical Reports Forecasted Profit for First Half of 2025

Major Shareholder of Luoxin Pharmaceutical Plans to Reduce Shareholding

Chemical Pharmaceutical Sector Continues to Rise

Roselin Pharma subsidiary obtains drug registration certificate for ibuprofen concentrated solution

Luoxin Pharmaceutical Reports Revenue Growth but Expanding Net Loss

Luoxin Pharmaceutical released FY2025 Q1 earnings on April 21 (BJT), actual revenue CNY 482.73 M, actual EPS CNY 0.01

LuoXin Pharmaceutical Reports a 115.41% Increase in Net Profit in Q1 2025

Luoxin Pharmaceutical released FY2024 Q4 earnings on April 14, 2025 (BJT), with actual revenue of CNY 766.45 M and EPS of CNY -0.6597

Luoxin Pharmaceutical released FY2024 earnings on April 14, 2025 (BJT), with actual revenue of CNY 2.647 B and EPS of CNY -0.9058

Luo Xin Pharmaceutical Q1 2025 Earnings Forecast

Luoxin Pharmaceutical Obtains Drug Registration Certificate for Levosalbutamol Inhalation Solution

Luoxin Pharmaceutical Obtains Approval for New Indication of Injection LX22001

Luoxin Pharmaceutical's 2024 Performance Forecast, Expected Net Loss of 785 Million to 985 Million Yuan

02513

002793

002589

In the morning session, the CPO concept strengthened again, with DSBJ hitting the daily limit, EverProX rising over 5% to continue setting new record highs, and LINKTEL TECHNOLOGIES, Huamao Technology, TACLINK, and CIG following the gains. Innovative drug stocks were active against the trend in the morning, with YIBAI PHARMACEUTICAL achieving three daily limits in six days, Menovo hitting the daily limit, and Jincheng Pharm, JINLING PHARM., Luoxin Pharmaceutical, and Realcan following the upward trend

Wallstreetcn

KNOWLEDGE ATLAS

Realcan

DSBJ

EverProX

JINLING PHARM.

TACLINK

Jincheng Pharm

Menovo

LINKTEL TECHNOLOGIES

YIBAI PHARMACEUTICAL

GTJA Allianz CSI All Share Semiconductors & Semiconductor Equipment ETF

Tianhong CSI Computer Theme ETF

GTJA Allianz SSE STAR Chip Design Thematic ETF

ChinaAMC SSE STAR Semiconductor Material & Equipment Thematic ETF

Guotai CSI Computer Theme ETF

China Southern CSI Semiconductor Industry Custom ETF

Guotai CES Semiconductor Chip Industry ETF

ChinaAMC Guozheng Semiconductor Chip ETF

A-share Three Major Indices Fell Collectively, Computing Hardware Active Against the Trend, Hang Seng Tech Index Down Over 1%, AI Large Model Stocks Rebound, KNOWLEDGE ATLAS Rises 7%

Luoxin Pharmaceutical announced that its controlling shareholder, Luoxin Holdings, recently released the pledge of 102 million shares and pledged 101 million shares. The released pledged shares account for 43.23% of its shareholding ratio and 9.42% of the company's total share capital; the pledged shares account for 42.75% of its shareholding ratio and 9.31% of the company's total share capital. As of the announcement date, Luoxin Holdings and its concerted parties have cumulatively pledged 137 million shares, accounting for 56.83% of the shareholding ratio and 12.63% of the company's total share capital. This pledge has no substantial impact on the company

Zhitong

Luoxin Pharmaceutical: The controlling shareholder has partially lifted the pledge of shares and re-pledged them

Luoxin Pharmaceutical announced that its revenue for the third quarter was 646 million yuan, a year-on-year increase of 3.94%; net profit was 5.2318 million yuan, a year-on-year increase of 102.96%. Revenue for the first three quarters was 1.723 billion yuan, a year-on-year decrease of 8.37%; net profit was 22.9268 million yuan, a year-on-year increase of 108.64%

Luoxin Pharmaceutical: Net profit in the third quarter was 5.2318 million yuan, a year-on-year increase of 102.96%

002424

The concept of innovative drugs continues the rebound momentum from yesterday, with GZBL and Luoxin Pharmaceutical hitting the daily limit, Sanofi's stock rising over 10%, and Laimei Pharmaceutical, Hainan Haiyao, Guangshengtang, and Yifang Biotechnology also following suit

GZBL

The concept of innovative drugs continues to rebound, with GZBL and Luoxin Pharmaceutical both hitting the daily limit

According to the Zhitong Finance APP, Luoxin Pharmaceutical disclosed its performance forecast for the first three quarters of 2025. The company expects a net profit attributable to shareholders of the listed company to be between 22.7 million yuan and 25.2 million yuan, turning a profit; the net profit after deducting non-recurring gains and losses is expected to be between 4.7 million yuan and 5.9 million yuan

Luoxin Pharmaceutical issued a profit warning, expecting a net profit attributable to the parent company of 22.7 million to 25.2 million yuan in the first three quarters, turning losses into profits

Luoxin Pharmaceutical announced that the secretary of the board, Han Fengsheng, has resigned due to a job transfer, and he will continue to serve in a position at the holding subsidiary after his resignation. The company held a board meeting on October 13, 2025, and decided to appoint Jiang Ying as the new secretary of the board, with a term until the end of the fifth board's term

Luoxin Pharmaceutical: Han Fengsheng resigns as board secretary, Jiang Ying takes over

Luoxin Pharmaceutical plans to issue A-shares to specific targets in the 2025 fiscal year, with a total fundraising amount not exceeding 842.4 million yuan. The number of issuance targets will not exceed 35, and the funds will be used for innovative drug research and development, the renovation and expansion of raw material drug production, and technical transformation projects for freeze-drying workshops, as well as to supplement working capital

Luoxin Pharmaceutical plans to raise no more than 842.4 million yuan through a private placement of shares

Luoxin Pharmaceutical announced that it will provide a joint liability guarantee of 10 million yuan for its holding subsidiary Luoxin Anruowei Pharmaceutical Co., Ltd. Previously, the company had been approved to guarantee a bank credit limit of 20 million yuan for it. The "Guarantee Contract" signed with the Agricultural Commercial Bank brings the company's guarantee balance for Luoan Company to 10 million yuan, with a remaining guarantee limit of 10 million yuan. The company's board of directors believes that the guarantee risk is controllable and aligns with overall interests

Luoxin Pharmaceutical provides joint liability guarantee for the 10 million debt of its holding subsidiary

Luoxin Pharmaceutical announced that its operating revenue in the first half of 2025 was 1.077 billion yuan, a year-on-year decrease of 14.45%. Net profit was 17.695 million yuan, a year-on-year increase of 119.95%

Luoxin Pharmaceutical: Net profit in the first half of 2025 was 17.695 million yuan, a year-on-year increase of 119.95%

300725

002370

603367

300683

688513

The pharmaceutical sector fluctuated and strengthened, with PHARMABLOCK rising over 15%. Multiple stocks, including Yatai pharm, CISEN, Zhongsheng Pharmaceutical, and Luoxin Pharmaceutical, hit the daily limit, while HITECK and EASTON BIOPHARMACEUTICALS surged

PHARMABLOCK

Yatai pharm

CISEN

HITECK

EASTON BIOPHARMACEUTICALS

The pharmaceutical sector fluctuates and strengthens, with multiple stocks hitting the daily limit

Luoxin Pharmaceutical(002793.SZ)